The analysts point to the company's sagging stock price, a product of investor fear that Johnson & Johnson may not be able to maintain its 10% annual growth rate, as one reason the company needs to make an acquisition and get investors excited again. The analysts said the more likely targets would be in the specialty drug concerns, such as Cephalon, Allergan or Forest Labs, and St. Jude Medical on the medical device side of the industry.

Related Summaries